AARD logo

Aardvark Therapeutics, Inc. Stock Price

NasdaqGS:AARD Community·US$93.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author
Create a narrative

AARD Share Price Performance

US$4.51
-5.50 (-54.95%)
​
US$4.51
-5.50 (-54.95%)
​
Price US$4.51

AARD Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
0 Rewards
View Full Analysis

Aardvark Therapeutics, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$69.9m

Other Expenses

-US$69.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-3.20
0%
0%
0%
View Full Analysis

About AARD

Founded
2017
Employees
40
CEO
Tien-Li Lee
WebsiteView website
aardvarktherapeutics.com

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Recent AARD News & Updates

Seeking Alpha • May 18

Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward

Summary Aardvark Therapeutics, Inc. faces a pivotal regulatory setback as the FDA placed a clinical hold on ARD-101 due to unexpected cardiac signals. AARD now trades as a cash-backed option, with the stock reflecting little value beyond its $91M cash position and a 1.15x price-to-book ratio. Unblinding pivotal trial data could provide rapid safety clarity, but risks trial integrity and likely necessitates an additional confirmatory Phase 3 study. I maintain a neutral/hold stance on AARD until there is clearer FDA guidance, as regulatory resolution is the critical near-term catalyst. Read the full article on Seeking Alpha

Recent updates

No updates

Aardvark Therapeutics, Inc. Competitors

CAMP logo

Camp4 Therapeutics

Symbol: NasdaqGM:CAMP
Market cap: US$233.7m
CHRS logo

Coherus Oncology

Symbol: NasdaqGM:CHRS
Market cap: US$232.9m
TNXP logo

Tonix Pharmaceuticals Holding

Symbol: NasdaqGS:TNXP
Market cap: US$231.1m
CAVG logo

ACC Aviation Holdings

Symbol: OTCPK:CAVG
Market cap: US$229.5m
View more competitors